Terms: = Prostate cancer AND CDK4, PSK-J3, 1019, ENSG00000135446, MGC14458, CMM3, P11802 AND Treatment
139 results:
1. [LncRNA RPL22P1-201 affects prostate cancer cell proliferation, cell cycle, and sensitivity to docetaxel by regulating miR-216b-5p expression].
Yang C; Xue JG
Zhonghua Nan Ke Xue; 2023 Oct; 29(10):881-887. PubMed ID: 38639656
[TBL] [Abstract] [Full Text] [Related]
2. Curcumin Enhances the Anti-cancer Efficacy of cdk4/6 Inhibitors in prostate cancer.
Zhao H; Ding R; Han J
Arch Esp Urol; 2024 Jan; 77(1):57-66. PubMed ID: 38374014
[TBL] [Abstract] [Full Text] [Related]
3. ER-positive and BRCA2-mutated breast cancer: a literature review.
Li PC; Zhu YF; Cao WM; Li B
Eur J Med Res; 2024 Jan; 29(1):30. PubMed ID: 38184581
[TBL] [Abstract] [Full Text] [Related]
4. [Metastatic castration-resistant prostate cancer-emerging trends in therapy].
von Amsberg G; Todenhöfer T
Urologie; 2023 Dec; 62(12):1289-1294. PubMed ID: 37955661
[TBL] [Abstract] [Full Text] [Related]
5. Targeted inhibition of mTOR by BML-275 induces mitochondrial-mediated apoptosis and autophagy in prostate cancer.
Li W; Li D; Ma Q; Chen Y; Hu Z; Bai Y; Xie L
Eur J Pharmacol; 2023 Oct; 957():176035. PubMed ID: 37657741
[TBL] [Abstract] [Full Text] [Related]
6. Long-term survival outcomes of salvage [
Ballal S; Yadav MP; Satapathy S; Raju S; Tripathi M; Damle NA; Sahoo RK; Bal C
Eur J Nucl Med Mol Imaging; 2023 Oct; 50(12):3777-3789. PubMed ID: 37462775
[TBL] [Abstract] [Full Text] [Related]
7. Veratramine Inhibits the Cell Cycle Progression, Migration, and Invasion via ATM/ATR Pathway in Androgen-Independent prostate cancer.
Kim HY; Lee SW; Choi SK; Ashim J; Kim W; Beak SM; Park JK; Han JE; Cho GJ; Ryoo ZY; Jeong J; Lee YH; Jeong H; Yu W; Park S
Am J Chin Med; 2023; 51(5):1309-1333. PubMed ID: 37385965
[TBL] [Abstract] [Full Text] [Related]
8. The ethanol extract of Cyperus exaltatus var. iwasakii exhibits cell cycle dysregulation, ERK1/2/p38 MAPK/AKT phosphorylation, and reduced MMP-9-mediated metastatic capacity in prostate cancer models in vitro and in vivo.
Kim H; Hwang B; Cho S; Kim WJ; Myung SC; Choi YH; Kim WJ; Lee S; Moon SK
Phytomedicine; 2023 Jun; 114():154794. PubMed ID: 37011419
[TBL] [Abstract] [Full Text] [Related]
9. [New treatment approaches for and ongoing trials in metastatic hormone-sensitive prostate cancer].
Isgandarov A; Darr C; Posdzich P; Hermann K; Hadaschik BA; Grünwald V
Urologie; 2023 Apr; 62(4):369-375. PubMed ID: 36823372
[TBL] [Abstract] [Full Text] [Related]
10. SETDB1 Modulates Degradation of Phosphorylated RB and Anticancer Efficacy of cdk4/6 Inhibitors.
Huang Z; Li X; Tang B; Li H; Zhang J; Sun R; Ma J; Pan Y; Yan B; Zhou Y; Ding D; Yan Y; Jimenez R; Orme JJ; Jin X; Yang J; Huang H; Jia Z
Cancer Res; 2023 Mar; 83(6):875-889. PubMed ID: 36637424
[TBL] [Abstract] [Full Text] [Related]
11. Decursin inhibits EGFR-ERK1/2 signaling axis in advanced human prostate carcinoma cells.
Bhat TA; Dheeraj A; Nambiar DK; Singh SP; Yim DS; Singh RP
Prostate; 2023 May; 83(6):534-546. PubMed ID: 36597263
[TBL] [Abstract] [Full Text] [Related]
12. Effect of prior treatments on post-CDK 4/6 inhibitor survival in hormone receptor-positive breast cancer.
Franks J; Caston NE; Elkhanany A; Gerke T; Azuero A; Rocque GB
Breast Cancer Res Treat; 2023 Feb; 197(3):673-681. PubMed ID: 36539670
[TBL] [Abstract] [Full Text] [Related]
13. Risk of prostate cancer and death after benign transurethral resection of the prostate-A 20-year population-based analysis.
Hilscher M; Røder A; Helgstrand JT; Klemann N; Brasso K; Vickers AJ; Stroomberg HV
Cancer; 2022 Oct; 128(20):3674-3680. PubMed ID: 35975979
[TBL] [Abstract] [Full Text] [Related]
14. Efficacy of open dialogue about complementary and alternative medicine compared with standard care in improving quality of life in patients undergoing conventional oncology treatment (CAMONCO 2): protocol for a randomised controlled trial.
Stie M; Delmar C; Nørgaard B; Jensen LH
BMJ Open; 2022 Apr; 12(4):e059960. PubMed ID: 35470199
[TBL] [Abstract] [Full Text] [Related]
15. A Genome-Wide CRISPR Activation Screen Identifies PRRX2 as a Regulator of Enzalutamide Resistance in prostate cancer.
Rodríguez Y; Unno K; Truica MI; Chalmers ZR; Yoo YA; Vatapalli R; Sagar V; Yu J; Lysy B; Hussain M; Han H; Abdulkadir SA
Cancer Res; 2022 Jun; 82(11):2110-2123. PubMed ID: 35405009
[TBL] [Abstract] [Full Text] [Related]
16. Biomarkers for Predicting Abiraterone treatment Outcome and Selecting Alternative Therapies in Castration-Resistant prostate cancer.
Qin S; Gao H; Kim W; Zhang H; Gu Y; Kalari KR; Sinnwell JP; Scholz JA; Xie F; Yin P; Yu J; Qin B; Zhuang Y; Wei L; Tan W; Bryce AH; Weinshilboum RM; Wang L
Clin Pharmacol Ther; 2022 Jun; 111(6):1296-1306. PubMed ID: 35288936
[TBL] [Abstract] [Full Text] [Related]
17. Exploiting the tumor-suppressive activity of the androgen receptor by cdk4/6 inhibition in castration-resistant prostate cancer.
Han W; Liu M; Han D; Toure AA; Li M; Besschetnova A; Wang Z; Patalano S; Macoska JA; Lam HM; Corey E; He HH; Gao S; Balk SP; Cai C
Mol Ther; 2022 Apr; 30(4):1628-1644. PubMed ID: 35121110
[TBL] [Abstract] [Full Text] [Related]
18. miRNA-214-5p inhibits prostate cancer cell proliferation by targeting SOX4.
Xu G; Meng Y; Wang L; Dong B; Peng F; Liu S; Li S; Liu T
World J Surg Oncol; 2021 Dec; 19(1):338. PubMed ID: 34863188
[TBL] [Abstract] [Full Text] [Related]
19. Cytotoxic Marine Alkaloid 3,10-Dibromofascaplysin Induces Apoptosis and Synergizes with Cytarabine Resulting in Leukemia Cell Death.
Spirin P; Shyrokova E; Lebedev T; Vagapova E; Smirnova P; Kantemirov A; Dyshlovoy SA; Amsberg GV; Zhidkov M; Prassolov V
Mar Drugs; 2021 Aug; 19(9):. PubMed ID: 34564151
[TBL] [Abstract] [Full Text] [Related]
20. PARP and cdk4/6 Inhibitor Combination Therapy Induces Apoptosis and Suppresses Neuroendocrine Differentiation in prostate cancer.
Wu C; Peng S; Pilié PG; Geng C; Park S; Manyam GC; Lu Y; Yang G; Tang Z; Kondraganti S; Wang D; Hudgens CW; Ledesma DA; Marques-Piubelli ML; Torres-Cabala CA; Curry JL; Troncoso P; Corn PG; Broom BM; Thompson TC
Mol Cancer Ther; 2021 Sep; 20(9):1680-1691. PubMed ID: 34158347
[TBL] [Abstract] [Full Text] [Related]
[Next]
